Half Yearly Report

29 September 2014

Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces its interim results for the six months ended 30 June 2014.

Operational highlights

• Data Access Licence and Royalty Agreement signed with Daymsa
• First commercial launch of products using Eden's GO-E™ technology in the biocides sector
• Three further grants of patents strengthening Eden's Intellectual Property portfolio
• Confirmation of Completeness-Check for dossier submitted to gain approval for lead plant protection product, 3AEY, using the Company's three EU approved active substances

Financial highlights

• Revenue for the period of £0.02m (H1 2013: £0.05m
• Operating Loss for the period, excluding amortization and share based payments, of £0.55m (H1 2013: £0.4m)Administrative expenses £0.57m (H1 2013: £0.45m)
• Cash at bank £0.08m (H1 2013: £0.40m)

Tom Lupton, Non-executive Chairman, said:

"The Operational Highlights above show the traction that Eden is rapidly gaining as it heads towards significant commercialization of products using its proprietary GO-E technology. As part of this progress, I am pleased to reiterate that, since the reporting period, Eden has strengthened its management team with the appointment of Sean Smith as Chief Executive Officer. Sean's experience in intellectual property, speciality chemicals and industrial biotechnology will, I believe, be very valuable to Eden as it advances into its next commercial phase.

"In addition to Sean's appointment, since the half year Eden announced that it has signed an exclusive evaluation agreement with Belgian speciality chemicals company Taminco BVBA for our nematicide product "B2Y". This is a potentially significant deal for Eden and is the first of a number of commercial arrangements which Eden expects to announce in the second half of 2014 in addition to news on the first EU approval of 3AEY, which will pave the way to further contractual milestone payments and royalties."

← Read other news articles